iPhone | iPad
Android
Huawei
While wknd. has consistently featured global stalwarts, we have kept our ear to the ground and documented the social and cultural changes taking place in the country
KT APPDOWNLOAD
Covid-19 in UAE: Over 23,000 high-risk patients treated with Sotrovimab
The anti-Covid medication has led to the recovery of 97.3% of UAE recipients with severe cases treated within 5-7 days
Photo: File
The Department of Health-Abu Dhabi (DoH), in partnership with GlaxoSmithKline, will research the effectiveness of the Covid-19 medication Sotrovimab and share it with the international medical community, enhancing the emirate's position as a leading destination for medical research.
The DoH and GlaxoSmithKline have expanded their research and use of Sotrovimab anti-Covid-19 medication, strengthening Abu Dhabi’s pandemic response and position as the regional life sciences hub.
Abu Dhabi is the first jurisdiction globally to share real-world evidence on the use of Sotrovimab in Covid-19 patients, following the treatment of more than 23,000 high-risk Covid-19 patients.
The UAE Capital was the first destination globally to receive Sotrovimab in June. Results have shown the anti-Covid-19 medication has led to the recovery of 97.3 per cent of UAE recipients with severe cases treated within 5-7 days.
The unified goals were translated through the signing of a Declaration of Collaboration that was signed by Dr. Jamal Mohammed Al Kaabi, Undersecretary of DoH and James Greenhalgh, Senior Vice President, GSK Growth Emerging Markets.
Earlier this year, DoH, with the support of GSK, secured innovative Covid-19 medication, Sotrovimab for the local healthcare sector.
Since the onset of the pandemic, Abu Dhabi has led an effective human-centred response based on collaboration and innovation with leading regional and international pharmaceutical companies.
ALSO READ:
The recently signed agreement aims to develop real-world evidence and capitalise on logistical processes related to Sotrovimab in support of regulatory decision-making and clinical trials. Additionally, the emirate will contribute to the international healthcare community by transferring lessons learned during this period and donating breakthrough treatment, Sotrovimab, as part of Abu Dhabi’s humanitarian efforts.
Dr. Jamal Mohammed Al Kaabi said: “Both the public and private sectors have worked in seamless harmony in the last couple of years and achieved great outcomes that resulted in Abu Dhabi marking its place on global listings and rankings. While the UAE continues to exhibit exemplary leadership through its response to the pandemic, we are committed to establishing a leading life science ecosystem in Abu Dhabi by driving clinical research and improving access to treatments and medical products.”
James Greenhalgh, Senior Vice President, GSK Growth Emerging Markets, stated: “Abu Dhabi has great potential to be a fast-rising hub in healthcare, life sciences and biopharmaceuticals. For decades, GSK has helped contribute to the health and well-being of Abu Dhabi’s citizens, and our new Declaration of Collaboration with the Department of Health enables us to increase our partnership in the emirate to further help the health of its people”.
More news from
The leading English daily newspaper marks its 46th anniversary today, delivering credible and comprehensive news to its readers across the UAE and beyond
Bank will continue to set the standard for digital excellence in the financial industry
This Coffee Table book presents a unique perspective on more than four decades of historical moments and futuristic aims
The group simplifies digital payments through their innovative products and services to customers all over the MEA region
Coverage of major international and local sports events is an integral part of the
Elevate your digital payment experience with state-of-the-art solutions, pioneering convenience & security
Business conglomerate expanding its footprint across the globe to deliver a variety of products and services
